2022.08.03 04:05

Thubrikar Aortic Valve announces initial 30-day outcomes of CE Mark-enabling TAVI-1 Study

Next-generation TAVI device demonstrates outstanding performance in initial patients in European pilot study.

The copyright of this article belongs to the original author/organization.
The current content only represents the author’s point of view, and has nothing to do with the position of Longbridge. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by Longbridge, please contact: